| Name | Title | Contact Details |
|---|
Skin Authority is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Prestige Care is a Washington-based provider of senior living and long-term care in the Western region of the United States. Founded in 1985, Prestige`s care philosophy is rooted in a set of shared core values that deliver on a promise to provide unmatched quality care, led by a compassionate heart. Across the company, Prestige team members strive to personally touch lives, guided by the four pillars of our core values: respect, integrity, commitment and trust. Prestige`s core values are instilled by the legacy of Sarah Delamarter, a pioneer in the long-term care industry. Today, Sarah`s legacy lives on through Prestige Care Inc, which includes 72 senior care communities across eight states. Prestige Care is a complete senior services organization, which provides Nursing and Rehabilitation services, Memory Care, and Assisted Living and Retirement Services. Prestige communities` commitment to excellence has been recognized by the American Healthcare Association with multiple Bronze and Silver quality care awards. In 2012 Prestige received the Innovators Award from the International Council on Active Aging® (ICAA), for its Expressions Memory Care program. Expressions is a life-affirming, activity-rich residential program for individuals with Alzheimer`s disease and other forms of dementia who seek community-based care to help alleviate the affects of the disease for patients and their families.
Medical Asset Management Inc is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
annual reviews is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.